ElutiaNASDAQ: ELUT

Profile

Sector:

Healthcare

Country:

United States

IPO:

08 October 2020

Next earnings report:

07 March 2025

Last dividends:

N/A

Next dividends:

N/A
$151.55 M
-2%vs. 3y high
50%vs. sector
-vs. 3y high
-vs. sector
-124%vs. 3y high
5%vs. sector
-2%vs. 3y high
66%vs. sector

Price

regular market | 28 min ago
$4.38+$0.20(+4.90%)

Dividend

No data over the past 3 years
$5.92 M$6.40 M
$5.92 M$1.29 M

Analysts recommendations

Institutional Ownership

ELUT Latest News

Elutia Inc. (ELUT) Q3 2024 Earnings Call Transcript
seekingalpha.com14 November 2024 Sentiment: NEUTRAL

Elutia Inc. (NASDAQ:ELUT ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants Matt Steinberg – FINN Partners Randy Mills – Chief Executive Officer Matt Ferguson – Chief Financial Officer Conference Call Participants Frank Takkinen – Lake Street Capital Markets Ross Osborn – Cantor Fitzgerald Operator Greetings. Welcome to the Elutia Third Quarter 2024 Financial Results Call.

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company's Antibiotic-Eluting BioEnvelope for Implantable Devices
globenewswire.com18 September 2024 Sentiment: POSITIVE

EluPro eradicated bacteria commonly associated with cardiac implant-related infections in an established preclinical infection model

Elutia Celebrates First Year
globenewswire.com06 September 2024 Sentiment: POSITIVE

Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment SILVER SPRING, Md., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, is celebrating its one-year anniversary and the team that made it possible.

Elutia Announces First Patient Implant of EluPro™, the World's First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
globenewswire.com05 September 2024 Sentiment: POSITIVE

SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world's first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.

Elutia to Participate in Upcoming Investor Conferences
globenewswire.com03 September 2024 Sentiment: POSITIVE

SILVER SPRING, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:

Elutia Inc. (ELUT) Q2 2024 Earnings Call Transcript
seekingalpha.com10 August 2024 Sentiment: NEUTRAL

Elutia Inc. (NASDAQ:ELUT ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matt Steinberg - Finn Partners, IR Randy Mills - President and CEO Matt Ferguson - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Frank Takkinen - Lake Street Capital Markets Operator Greetings. Welcome to the Elutia Second Quarter 2024 Financial Results Call.

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
globenewswire.com31 July 2024 Sentiment: POSITIVE

SILVER SPRING, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced the appointment of Ryan Marques, Ph.D, MBA as Vice President of Operations. Dr. Marques brings more than 20 years of experience leading operations teams across manufacturing, quality assurance, supply chain and technical services in the device and pharmaceutical industries.

Elutia to Present at the Emerging Growth Conference on Thursday, July 18
globenewswire.com11 July 2024 Sentiment: POSITIVE

SILVER SPRING, Md., July 11, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the Emerging Growth Conference on Thursday, July 18, 2024, at 12:35 p.m. ET (9:35 a.m. PT).

Elutia Announces $13.26 Million Registered Direct Offering
globenewswire.com17 June 2024 Sentiment: POSITIVE

SILVER SPRING, Md., June 17, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”) today announced it has entered into a definitive agreement with investors for the purchase and sale of 3,175,000 shares of the Company's Class A common stock at a purchase price of $3.40 per share and 725,000 prefunded warrants to purchase up to 725,000 shares of the Company's Class A common stock at a purchase price of $3.399 per prefunded warrant in a registered direct offering. The prefunded warrants are immediately exercisable at an exercise price of $0.001 per each prefunded warrant. The gross proceeds to Elutia from the offering are expected to be approximately $13.26 million, before deducting placement agent fees and other offering expenses payable by Elutia. The offering is expected to close on or about June 18, 2024, subject to customary closing conditions.

Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
globenewswire.com17 June 2024 Sentiment: POSITIVE

EluPro becomes the only drug-eluting biologic envelope to receive FDA clearance in the $600 million U.S. implantable electronic device protection market

What type of business is Elutia?

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

What sector is Elutia in?

Elutia is in the Healthcare sector

What industry is Elutia in?

Elutia is in the Medical Devices industry

What country is Elutia from?

Elutia is headquartered in United States

When did Elutia go public?

Elutia initial public offering (IPO) was on 08 October 2020

What is Elutia website?

https://elutia.com

Is Elutia in the S&P 500?

No, Elutia is not included in the S&P 500 index

Is Elutia in the NASDAQ 100?

No, Elutia is not included in the NASDAQ 100 index

Is Elutia in the Dow Jones?

No, Elutia is not included in the Dow Jones index

When was Elutia the previous earnings report?

No data

When does Elutia earnings report?

The next expected earnings date for Elutia is 07 March 2025